Back to Dashboard










Moderna, Inc. (MRNA)
Real-time intraday values
Market Overview
From:
To:
MRNA Intraday
No data available
SymbolMRNA
IPO DateDec 7, 2018
CEOMr. Stéphane Bancel M.B.A.
Full Time Employees4.7k
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNasdaqGS
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -3.88% | -8.73 US$ |
| 5 Days | +10.07% | +19.79 US$ |
| 1 Month | +50.22% | +72.30 US$ |
| 6 Months | +298.58% | +162.01 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of MRNA...
Key Statistics
Market Cap
86.33B
P/E Ratio
N/A
Div Yield
0.00%
52W High
$227.46
52W Low
$22.28
Analyst Consensus
ConsensusHold
Bullish521.7%
Neutral1460.9%
Bearish417.4%
52W Analyst Price Targets
Min Target
$45.00
$45.00
Max Target
$200.00
$200.00
Current$216.27
Avg Target$122.67
Analyst Recommendations
Target Price:$122.67($45.00 - $200.00)
Community Thoughts
Share your analysis and sentiment on MRNA
Join the community to share your analysis
Latest News for MRNA

BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles
Stocktwits•Oct 13, 2026, 11:14 PM
BioNTech mRNA cancer immunotherapy misses first objective in key study
BioPharma Dive•Oct 13, 2026, 04:24 PM

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Zacks•Oct 13, 2026, 03:01 PM

Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
PR Newswire•Oct 13, 2026, 01:02 PM

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool•Oct 13, 2026, 12:37 PM

Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
ACCESS Newswire•Oct 13, 2026, 11:00 AM


Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Motley Fool•Oct 13, 2026, 09:04 AM
Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines
TIKR•Oct 13, 2026, 02:23 AM

Where Could Moderna's Next Growth Come From?
Trefis•Oct 12, 2026, 09:01 PM